April 2025

UROLOGY

NAVIGATING THE RECENT APPROVAL OF NEOADJUVANT DURVALUMAB FOR MUSCLE-INVASIVE BLADDER CANCER

In an interview with UrologyTimes, Joshua J. Meeks, MD, PhD, discussed the recent FDA approval of durvalumab (Imfinzi) in combination with gemcitabine and cisplatin for neoadjuvant use, followed by adjuvant durvalumab monotherapy after radical cystectomy for adults with muscle-invasive bladder cancer. The approval is a milestone in the use of immunotherapy in the neoadjuvant setting.
​
Dr. Meeks offers key insights on:
  • How the NIAGARA trial, a randomized, open-label, multicenter, phase 3 trial with over a thousand patients, is changing the way we treat muscle-invasive bladder cancer
  • Why it’s important to bring immunotherapy into the picture earlier
  • The implications for surgical decision-making and post-op care following radical cystectomy
Joshua Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD, Professor of Urology and Associate Professor of Biochemistry and Molecular Genetics at Northwestern Medicine

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like